Sunday, 3 March 2024

Business News

AN2 Therapeutics downgraded to Market Perform from Outperform at Leerink – TipRanks Financial Blog

Danaher Corporation Reported Earnings Today. Is it a Beat?

Leerink analyst Joseph Schwartz downgraded AN2 Therapeutics to Market Perform from Outperform with a $7 price target after the company decided to voluntarily pause Phase 3 enrollment in its Phase 2/3 clinical trial evaluating epetraborole in treatment-refractory mycobacterium avium complex lung disease, pending further data review.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on ANTX:

Click Here to Read the Full Original Article at TipRanks Financial Blog…